Joseph Hulihan
Overview
Explore the profile of Joseph Hulihan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
598
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Olson H, Amin S, Bahi-Buisson N, Devinsky O, Marsh E, Pestana-Knight E, et al.
Epilepsia
. 2023 Nov;
65(1):37-45.
PMID: 37950390
Objective: In the placebo-controlled, double-blind phase of the Marigold study (NCT03572933), ganaxolone significantly reduced major motor seizure frequency (MMSF) in patients with cyclin-dependent kinase-like 5 deficiency disorder (CDD). We report...
2.
Singh R, Singh R, Stewart A, Van Poppel K, Klinger S, Hulihan J, et al.
Epilepsy Behav Rep
. 2022 Nov;
20:100567.
PMID: 36325100
Synaptic GABA receptor (GABAR) internalization contributes to the drug resistant nature of super-refractory status epilepticus (SRSE). Ganaxolone is a 3β-methylated synthetic analog of the endogenous neuroactive steroid, allopregnanolone, that has...
3.
Buchhalter J, Neuray C, Cheng J, DCruz O, Datta A, Dlugos D, et al.
Epilepsy Res
. 2022 Oct;
187:107028.
PMID: 36270075
Introduction: The lack of ideal measurement of treatment efficacy is a well acknowledged problem in the epilepsy community, both in clinical care and clinical trials. Whilst still the current gold-standard,...
4.
Guterman E, Betjemann J, Aimetti A, Li J, Wang Z, Yin D, et al.
JAMA Neurol
. 2021 Apr;
78(5):588-595.
PMID: 33818596
Importance: Status epilepticus (SE) is associated with poor clinical outcomes and high cost. Increased levels of refractory SE require treatment with additional medications and carry increased morbidity and mortality, but...
5.
Alphs L, Bossie C, Sliwa J, Fu D, Ma Y, Hulihan J
Neuropsychiatr Dis Treat
. 2013 Mar;
9:341-50.
PMID: 23493643
Background: This post hoc subgroup analysis of a randomized, double-blind trial evaluated the response to treatment with two long-acting injectable atypical antipsychotics, ie, paliperidone palmitate and risperidone long-acting injectable (RLAI),...
6.
Alphs L, Olson W, Turkoz I, Fastenau J, Hulihan J
J Clin Psychiatry
. 2012 Nov;
73(10):1358.
PMID: 23140655
No abstract available.
7.
Lipton R, Silberstein S, Dodick D, Cady R, Freitag F, Mathew N, et al.
Cephalalgia
. 2010 Oct;
31(1):18-30.
PMID: 20974598
Objective: The study sought to evaluate whether topiramate prevents development of chronic daily headache (CDH, ≥15 headache days per month) in adult subjects with high-frequency episodic migraine (HFEM, 9-14 migraine...
8.
Ramsay E, Faught E, Krumholz A, Naritoku D, Privitera M, Schwarzman L, et al.
Epilepsia
. 2010 Jul;
51(10):1970-7.
PMID: 20633037
Purpose: To evaluate topiramate (TPM) and phenytoin (PHT) monotherapy following rapid oral initiation in new-onset epilepsy. Methods: Randomized, double-blind, 28-day trial of TPM (100 mg/day beginning on day 1) versus...
9.
Elble R, Biondi D, Ascher S, Wiegand F, Hulihan J
Mov Disord
. 2010 Mar;
25(5):634-8.
PMID: 20201005
The efficacy and safety of carisbamate, an investigational neuromodulator currently in development for epilepsy, were examined in a multicenter, randomized, double-blind, cross-over, placebo-controlled study of essential tremor. Sixty-two patients (intent-to-treat...
10.
Silberstein S, Lipton R, Dodick D, Freitag F, Mathew N, Brandes J, et al.
Headache
. 2009 Sep;
49(8):1153-62.
PMID: 19719543
Objective: To define yet more clearly the utility of topiramate in the treatment of chronic migraine, we evaluated prespecified secondary endpoints from a recent randomized, double-blind, placebo-controlled, multicenter clinical trial....